AZD0305 Trial
Phase 1/2
226
about 3.3 years
18+
9 sites in CA, GA, MA +5
About this study
Researchers are testing AZD0305 as a treatment for relapsed/refractory multiple myeloma. The trial will evaluate the safety, tolerability, and effectiveness of AZD0305 in adults with this condition.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take AZD0305
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only)
Secondary: Phase Ia: Duration of response (DoR), Phase Ia: Objective Response Rate (ORR), Phase Ia: Overall Survival (OS), Phase Ia: Pharmacokinetics of AZD0305: Area Under the concentration-time curve (AUC), Phase Ia: Pharmacokinetics of AZD0305: Clearance, Phase Ia: Pharmacokinetics of AZD0305: Maximum plasma concentration of the study drug (Cmax), Phase Ia: Pharmacokinetics of AZD0305: Terminal elimination half-life (t 1/2), Phase Ia: Pharmacokinetics of AZD0305: Time to maximum plasma concentration of the study drug (tmax)
Oncology